MA44862A - Formulations de fulvestrant et méthodes d'utilisation de celles-ci - Google Patents
Formulations de fulvestrant et méthodes d'utilisation de celles-ciInfo
- Publication number
- MA44862A MA44862A MA044862A MA44862A MA44862A MA 44862 A MA44862 A MA 44862A MA 044862 A MA044862 A MA 044862A MA 44862 A MA44862 A MA 44862A MA 44862 A MA44862 A MA 44862A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- fulvestrant formulations
- fulvestrant
- formulations
- Prior art date
Links
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 title 1
- 229960002258 fulvestrant Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332842P | 2016-05-06 | 2016-05-06 | |
| US201662420555P | 2016-11-10 | 2016-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44862A true MA44862A (fr) | 2019-03-13 |
Family
ID=58709642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA044862A MA44862A (fr) | 2016-05-06 | 2017-05-05 | Formulations de fulvestrant et méthodes d'utilisation de celles-ci |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20190134059A1 (OSRAM) |
| EP (1) | EP3452011A1 (OSRAM) |
| JP (3) | JP2019516789A (OSRAM) |
| KR (1) | KR102438425B1 (OSRAM) |
| CN (1) | CN109310621A (OSRAM) |
| AU (2) | AU2017261321B2 (OSRAM) |
| CA (1) | CA3022834A1 (OSRAM) |
| CO (1) | CO2018013257A2 (OSRAM) |
| IL (2) | IL285928B2 (OSRAM) |
| MA (1) | MA44862A (OSRAM) |
| MX (2) | MX2018013414A (OSRAM) |
| MY (1) | MY205661A (OSRAM) |
| UA (1) | UA125514C2 (OSRAM) |
| WO (1) | WO2017193048A1 (OSRAM) |
| ZA (1) | ZA201807031B (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11590077B2 (en) | 2016-05-06 | 2023-02-28 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations and methods of their use |
| MY204442A (en) * | 2017-11-08 | 2024-08-28 | Eagle Pharmaceuticals Inc | Fulvestrant formulations and methods of their use |
| US12377049B2 (en) * | 2019-12-11 | 2025-08-05 | Shanghai Bocimed Pharmaceutical Co., Ltd. | Fulvestrant pharmaceutical composition, preparation method therefor, and application thereof |
| CN113694017B (zh) * | 2020-05-11 | 2024-04-02 | 鲁南制药集团股份有限公司 | 一种氟维司群注射制剂及其制备方法 |
| CN114504551B (zh) * | 2020-11-16 | 2024-01-02 | 北京厚燊维康科技有限责任公司 | 可用于光动力治疗或诊断的制剂 |
| WO2022121961A1 (zh) * | 2020-12-10 | 2022-06-16 | 上海博志研新药物技术有限公司 | 氟维司群药物组合物、其制备方法及应用 |
| KR20230094172A (ko) * | 2021-12-20 | 2023-06-27 | 주식회사 삼양홀딩스 | 용해도가 개선된 풀베스트란트의 약학 조성물 및 그 제조 방법 |
| KR20240105964A (ko) * | 2022-12-29 | 2024-07-08 | 주식회사 삼양홀딩스 | 약동학적 특성이 우수한 풀베스트란트의 약학 조성물 및 그 제조 방법 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| WO2001087262A2 (en) | 2000-05-15 | 2001-11-22 | Pharmacia Italia S.P.A. | Stabilized steroidal suspension |
| US6495534B2 (en) * | 2000-05-15 | 2002-12-17 | Pharmacia & Upjohn Spa | Stabilized aqueous suspensions for parenteral use |
| GB0116619D0 (en) * | 2001-07-07 | 2001-08-29 | Astrazeneca Ab | Formulation |
| RU2004102393A (ru) * | 2001-07-07 | 2005-03-27 | Астразенека Аб (Se) | Фармацевтическая композиция для внутримышечного введения фульвестранта |
| JP2003298516A (ja) | 2002-03-29 | 2003-10-17 | Fujitsu Ltd | 波長分散補償装置 |
| PL1778187T3 (pl) | 2004-08-04 | 2012-09-28 | Camurus Ab | Kompozycje tworzące nielamelarne dyspersje |
| US8226926B2 (en) | 2005-05-09 | 2012-07-24 | Biosphere Medical, S.A. | Compositions and methods using microspheres and non-ionic contrast agents |
| CA2626016A1 (en) | 2005-10-21 | 2007-06-21 | Panacea Biotec Limited | Pharmaceutical composition comprising at least one anticancer drug and at least one polymer |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| CN101108168B (zh) * | 2007-08-03 | 2010-12-08 | 西安力邦医药科技有限责任公司 | 一种氟维司群缓释微球的制备方法 |
| EP2200588B1 (en) | 2007-09-25 | 2019-03-20 | Solubest Ltd. | Compositions comprising lipophilic active compounds and method for their preparation |
| CA2716576A1 (en) | 2008-03-07 | 2009-09-11 | Nageswara R. Palepu | Fulvestrant formulations |
| TW201016220A (en) * | 2008-10-31 | 2010-05-01 | Scinopharm Taiwan Ltd | Micronization form of 7α-[9-(4,4,5,5,5-pentafluoropentylsufinyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol and process for the preparation thereof |
| SG176929A1 (en) | 2009-06-18 | 2012-01-30 | Abbott Lab | Stable nanoparticulate drug suspension |
| JP5675803B2 (ja) * | 2009-07-31 | 2015-02-25 | シーアン リーバン メディカル テクノロジー シーオー．， エルティーディーＸｉ’Ａｎ Ｌｉｂａｎｇ Ｍｅｄｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ | ミクロスフェア薬物担体、調製方法、組成物及びその使用 |
| EP2417975A4 (en) * | 2009-08-31 | 2012-11-14 | Xi An Libang Medical Technology Co Ltd | FULVESTRANT NANOPERLENES / MICROPERLES AND MANUFACTURING METHOD AND USE |
| WO2012021791A2 (en) | 2010-08-13 | 2012-02-16 | Scidose Llc | Aqueous formulation with improved stability |
| BR112013006331B1 (pt) | 2010-09-16 | 2021-09-21 | Shimoda Biotech (Pty) Ltd | Formulação compreendendo fulvestranto e ciclodextrina e seu uso |
| EP2468258A1 (en) | 2010-12-22 | 2012-06-27 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient |
| WO2012094620A2 (en) | 2011-01-09 | 2012-07-12 | Anp Technologies, Inc. | Hydrophobic molecule-induced branched polymer aggregates and their use |
| ES2708302T3 (es) * | 2011-05-20 | 2019-04-09 | Capital Business Y Gestion De Finanzas S L | Composición farmacéutica |
| CN102915088A (zh) | 2011-08-03 | 2013-02-06 | 鸿富锦精密工业（深圳）有限公司 | 资料存储器固定装置 |
| US11179468B2 (en) * | 2012-04-09 | 2021-11-23 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations |
| ES2983451T3 (es) | 2012-04-09 | 2024-10-23 | Eagle Pharmaceuticals Inc | Formulaciones de Fulvestrant |
| EP2858666B1 (en) * | 2012-06-08 | 2019-09-04 | F.Hoffmann-La Roche Ag | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
| CN104337761B (zh) * | 2013-08-07 | 2019-03-26 | 江苏豪森药业集团有限公司 | 氟维司群药物组合物 |
| JP2016529308A (ja) * | 2013-09-06 | 2016-09-23 | サラー ウッディン アハメド， | フルベストラント組成物 |
| JP2016536282A (ja) * | 2013-10-03 | 2016-11-24 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ＰＩ３Ｋα阻害剤を使用する強化された治療レジメン |
| HUP1300646A2 (en) | 2013-11-12 | 2015-05-28 | Druggability Technologies Ip Holdco Jersey Ltd | Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| PT107433B (pt) | 2014-01-28 | 2018-12-04 | Hovione Farm S A | Processo de redução e controlo do tamanho de partícula |
| US9271990B2 (en) | 2014-02-14 | 2016-03-01 | Fresenius Kabi Usa, Llc | Fulvestrant formulations |
| EP3164111B1 (en) | 2014-07-02 | 2019-04-03 | The Research Foundation for the State University of New York | Surfactant-stripped micelle compositions with high cargo to surfactant ratio |
| WO2015018380A2 (en) | 2014-07-03 | 2015-02-12 | Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang)Co., Ltd. | Therapeutic nanoparticles and the preparation methods thereof |
-
2017
- 2017-05-04 IL IL285928A patent/IL285928B2/en unknown
- 2017-05-05 MX MX2018013414A patent/MX2018013414A/es unknown
- 2017-05-05 JP JP2019510578A patent/JP2019516789A/ja active Pending
- 2017-05-05 WO PCT/US2017/031376 patent/WO2017193048A1/en not_active Ceased
- 2017-05-05 US US16/099,265 patent/US20190134059A1/en not_active Abandoned
- 2017-05-05 CN CN201780027809.5A patent/CN109310621A/zh active Pending
- 2017-05-05 UA UAA201812019A patent/UA125514C2/uk unknown
- 2017-05-05 MA MA044862A patent/MA44862A/fr unknown
- 2017-05-05 EP EP17723902.7A patent/EP3452011A1/en active Pending
- 2017-05-05 CA CA3022834A patent/CA3022834A1/en active Pending
- 2017-05-05 AU AU2017261321A patent/AU2017261321B2/en active Active
- 2017-05-05 KR KR1020187034942A patent/KR102438425B1/ko active Active
- 2017-05-05 MY MYPI2018703903A patent/MY205661A/en unknown
-
2018
- 2018-10-18 IL IL262465A patent/IL262465A/en unknown
- 2018-10-22 ZA ZA2018/07031A patent/ZA201807031B/en unknown
- 2018-11-01 MX MX2022013199A patent/MX2022013199A/es unknown
- 2018-12-06 CO CONC2018/0013257A patent/CO2018013257A2/es unknown
-
2021
- 2021-07-19 JP JP2021118471A patent/JP7312523B2/ja active Active
- 2021-07-19 US US17/379,534 patent/US12370199B2/en active Active
-
2023
- 2023-05-26 JP JP2023086732A patent/JP2023109959A/ja active Pending
- 2023-05-31 AU AU2023203392A patent/AU2023203392A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190005183A (ko) | 2019-01-15 |
| CO2018013257A2 (es) | 2018-12-28 |
| NZ747911A (en) | 2025-03-28 |
| ZA201807031B (en) | 2023-10-25 |
| AU2017261321A1 (en) | 2018-11-15 |
| AU2017261321B2 (en) | 2023-03-09 |
| JP7312523B2 (ja) | 2023-07-21 |
| CA3022834A1 (en) | 2017-11-09 |
| IL285928A (en) | 2021-10-31 |
| RU2018142068A (ru) | 2020-06-08 |
| EP3452011A1 (en) | 2019-03-13 |
| CN109310621A (zh) | 2019-02-05 |
| US12370199B2 (en) | 2025-07-29 |
| MX2018013414A (es) | 2019-06-06 |
| UA125514C2 (uk) | 2022-04-13 |
| JP2023109959A (ja) | 2023-08-08 |
| US20190134059A1 (en) | 2019-05-09 |
| KR102438425B1 (ko) | 2022-09-01 |
| AU2023203392A1 (en) | 2023-06-29 |
| IL262465A (en) | 2018-12-31 |
| RU2018142068A3 (OSRAM) | 2020-09-17 |
| JP2019516789A (ja) | 2019-06-20 |
| MX2022013199A (es) | 2022-12-13 |
| JP2021169510A (ja) | 2021-10-28 |
| US20210346396A1 (en) | 2021-11-11 |
| IL285928B1 (en) | 2025-02-01 |
| IL285928B2 (en) | 2025-06-01 |
| MY205661A (en) | 2024-11-04 |
| WO2017193048A1 (en) | 2017-11-09 |
| BR112018072768A2 (pt) | 2019-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3402549A4 (en) | MICRONADELE COMPOSITIONS AND METHOD FOR USE THEREOF | |
| MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
| EP3429591A4 (en) | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | |
| EP3694529A4 (en) | TRISPECIFIC PROTEINS AND METHOD OF USE | |
| MA49403A (fr) | Compositions de pde5 et méthodes d'immunothérapie | |
| MA48579A (fr) | Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci | |
| MA43387A (fr) | Anticorps anti-gitr et leurs méthodes d'utilisation | |
| MA45123A (fr) | Anticorps anti-tim-3 et leurs méthodes d'utilisation | |
| EP3383430A4 (en) | ANTIBODIES AND METHOD FOR USE THEREOF | |
| MA42243A (fr) | Anticorps de facteur xi et méthodes d'utilisation | |
| EP3373969A4 (en) | GLYCANINTERAGING COMPOUNDS AND METHOD OF USE | |
| MA44862A (fr) | Formulations de fulvestrant et méthodes d'utilisation de celles-ci | |
| EP3319611A4 (en) | OXYSTEROLS AND METHOD OF USE THEREOF | |
| EP3393382A4 (en) | OPHTHALMIC KNIFE AND METHOD OF USE | |
| MA48595A (fr) | Anticorps anti-tau et leurs méthodes d'utilisation | |
| MA44955A (fr) | Anticorps anti-tau et leurs méthodes d'utilisation | |
| EP3383917A4 (en) | Novel anti-claudin antibodies and methods of use | |
| EP3474857A4 (en) | COMPOSITIONS AND METHOD FOR DELIVERING THERAPY AGENTS | |
| MA44526A (fr) | Oxystérols et leurs méthodes d'utilisation | |
| EP3525583A4 (en) | ANTI-CS1 ANTIBODIES AND METHOD FOR USE THEREOF | |
| MA43284A (fr) | Composés et leurs méthodes d'utilisation | |
| EP3551209A4 (en) | INSULIN FC FUSIONS AND METHOD FOR USE | |
| EP3728323A4 (en) | ANTI-FRIZZLED ANTIBODIES AND METHODS OF USE | |
| EP3684819A4 (en) | Anti-ykl40 antibodies and methods of use | |
| MA43282A (fr) | Nouveaux anticorps anti-emr2 et méthodes d'utilisation associées |